Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting RNA-Modifying Proteins Portfolio News / By admin May 18, 2018
Escient Pharmaceuticals Launches with $40 Million Series A Financing to Advance First-in-Class G Protein-Coupled Receptor (GPCR)-Targeted Drugs to Address Serious, Unserved Medical Needs Portfolio News / By admin May 9, 2018
